Skip to main content
Article
Porcine reproductive and respiratory syndrome virus enters cells through a low pH-dependent endocytic pathway
Virus Research (1996)
  • Luiz C. Kreutz, United States Department of Agriculture
  • Mark R. Ackermann, United States Department of Agriculture
Abstract

The entry pathway of porcine reproductive and respiratory syndrome virus (PRRSV) into MARC-145 cells was investigated using a variety of drugs that interfere with the pH of intracellular vesicles by different mechanisms. Virus entry was assessed by measuring viral RNA replication or production of infectious virus. Chloroquine, ammonium chloride and bafilomycin A1 inhibited RNA replication or production of infectious virus in a dose-dependent manner. These drugs inhibited virus replication when added to the cells prior to, at infection or soon after infection. Moreover, the effect of chloroquine on PRRSV replication was reversible under acidic conditions of the media. Taken together, these results indicated that a low pH was required during virus entry. Electron microscopic data showed virus particles at the cell surface or within small vesicles which were circumscribed by a clathrin-like zone. In addition, the number of PRRSV-infected cells was decreased in the presence of cytochalasin B and phenylarsine oxide. Thus, we concluded that PRRSV entry might occur through a microfilament-dependent endocytic mechanism in which a low pH is necessary for proper virus uncoating.

Keywords
  • Porcine reproductive,
  • respiratory syndrome virus,
  • Virus entry mechanism,
  • Endocytosis
Publication Date
June, 1996
Publisher Statement
Works produced by employees of the U.S. Government as part of their official duties are not copyrighted within the U.S. The content of this document is not copyrighted.
Citation Information
Luiz C. Kreutz and Mark R. Ackermann. "Porcine reproductive and respiratory syndrome virus enters cells through a low pH-dependent endocytic pathway" Virus Research Vol. 42 Iss. 1–2 (1996)
Available at: http://works.bepress.com/mark_ackermann/75/